Inclusion Criteria:

- The patient must give written (personally signed and dated) informed consent for
their data to be included in the database for this Post Marketing Surveillance
programme and any subsequent analysis.

- The patient must have been receiving treatment with Somatuline Autogel at a stable
dose for at least 4 months.

- The patient must have a diagnosis of neuroendocrine tumours

- The patient must be at least 18 years of age

- For patients receiving or intending to receive Somatuline Autogel by home injection:

- The patient must be able to store Somatuline Autogel safely in a refrigerator in
their own home and either collect it from their GP/Pharmacy on a monthly basis,
or receive the medication by a home delivery service.

Exclusion Criteria:

- The patient is pregnant or breast-feeding, unless continued treatment with Somatuline
Autogel is clearly needed (as determined by the treating clinician).